Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133 + cancer stem-like cells in ovarian cancer

Oncogene

Volumn 34, Issue 2, 2015, Pages 165-176

  Xiang, T ^a   Long, H ^a   He, L ^a   Han, X ^a   Lin, K ^a   Liang, Z ^a   Zhuo, W ^a   Xie, R ^a   Zhu, B ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

cancer stem cells; IL 17; ovarian cancer; self renewal

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; INTERLEUKIN 17; LEUKOCYTE ANTIGEN; PEPTIDE;

ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HETEROGRAFTS; HUMANS; INTERLEUKIN-17; MICE; MICE, NUDE; MICE, SCID; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84890522862     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.537     Document Type: Article

References (50)

1. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
2. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102: 1276-1283.
3. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
4. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-2883.
5. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al. Epigenetic regulation of CD133 and tumorigenicity of CD133\+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
6. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16: 3113-3120.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
8. Pasquier J, Rafii A. Role of the microenvironment in ovarian cancer stem cell maintenance. BioMed Res Int 2013; 2013: 630782.
9. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
10. Yi L, Xiao H, Xu M, Ye X, Hu J, Li F et al. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 2011; 232: 75-82.
11. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH et al. CD44\+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8: R59.
12. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
13. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
14. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010; 120: 485-497.
15. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, Croce M et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011; 103: 1884-1898.
16. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150: 5445-5456.
17. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008; 10: R95.
18. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57: 772-779.
19. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14: 3254-3261.
20. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171-182.
21. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4\+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 15505-15510.
22. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001; 282: 735-738.
23. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169-4175.
24. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 1998; 273: 27467-27473.
25. Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem Biophys Res Commun 1999; 262: 14-19.
26. Subramaniam SV, Pearson LL, Adunyah SE. Interleukin-17 induces rapid tyrosine phosphorylation and activation of raf-1 kinase in human monocytic progenitor cell line U937. Biochem Biophys Res Commun 1999; 259: 172-177.
27. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006; 281: 35603-35607.
28. Shostak K, Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 2011; 13: 214.
29. Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 2006; 15: 1894-1913.
30. Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z et al. Autocrine CCL5 signaling promotes invasion and migration of CD133\+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012; 30: 2309-2319.
31. Kusumbe AP, Mali AM, Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009; 27: 498-508.
32. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F et al. IL-17 enhances the net angiogenic activity and in vivo growth of human nonsmall cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175: 6177-6189.
33. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
34. Filatova A, Acker T, Garvalov BK. The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta 2013; 1830: 2496-2508.
35. Hamilton TC, Foster BJ, Grotzinger KR, McKoy W, Young RC, Ozols RF. Development of drug-sensitive and-resistant human ovarian cancer cell lines. Proc Am Assoc Cancer Res 1983; 24: 313.
36. Ciucci A, De Stefano I, Vellone VG, Lisi L, Bottoni C, Scambia G et al. Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival. PLoS One 2013; 8: e60145.
37. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4: 2126.
38. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160: 3513-3521.
39. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-584.
40. Lai D, Wang F, Chen Y, Wang C, Liu S, Lu B et al. Human ovarian cancer stem-like cells can be efficiently killed by gammadelta T lymphocytes. Cancer Immunol Immunother 2012; 61: 979-989.
41. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J et al. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013; 352: 351-359.
42. Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF-and VEGF-induced growth of vascular endothelial cells. Immunol Lett 2005; 98: 189-193.
43. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factoralpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004; 93: 39-43.
44. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010; 101: 2384-2390.
45. Du JW, Xu KY, Fang LY, Qi XL. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep 2012; 6: 1099-1102.
46. Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J et al. Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2(\+) glial cells. Nat Neurosci 2013; 16: 1401-1408.
47. Villalva C, Martin-Lanneree S, Cortes U, Dkhissi F, Wager M, Le Corf A et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer 2011; 128: 826-838.
48. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
49. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
50. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-235.